Altretamine is an antineoplastic agent used in palliative treatment of persistent or recurrent ovarian cancer. It also acts as a chemosterilant for male houseflies and other insects.
- Mechanism
- Curator reviewed
The precise mechanism by which altretamine exerts its cytotoxic effect is unknown although it is classified as an alkylating anti-neoplastic agent. Through this mechanism, the drug is metabolized into alkylating agents by N-demethylation. These alkylating species consequently damage tumor cells.
- Primary indication
- For use as a single agent in the palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent-based combination.Curator reviewed
- Formula / weight
- C9H18N6 · 210.2794 g/mol (avg)
- First approval
- Canada, 2011 · United States, 1990
- Also known as
- Hexamethylmelamine
- Code names
- NSC-13875 · RB 1515
Resolves to
Clinical / RWD
Structure
InChIKey
UUVWYPNAQBNQJQ-UHFFFAOYSA-NSMILESCN(C)C1=NC(=NC(=N1)N(C)C)N(C)CWhat you can answer from here — as of September 12, 2026
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which companies are running trials of Altretamine, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account